Related Experiment Video

Updated: Jun 3, 2026

Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
11:50

Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit

Published on: January 7, 2020

[Implementation of the neonatal cystic fibrosis screening program in Switzerland: beginning January 2011]

Anne Mornand1, Jürg Barben, Gaudenz Hafen

  • 1Unité de pneumologie pédiatrique, Hôpital des enfants, Rue Willy Donzé 6, 1211 Geneve 14. anne.mornand@hcuge.ch

Revue Medicale Suisse
|April 2, 2011
PubMed

Insights

Newborn screening for cystic fibrosis (CF) in Switzerland began in 2011. This program aims to reduce diagnostic delays and enable early intervention for respiratory and nutritional issues, improving patient outcomes.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Context:

  • Delayed diagnosis of cystic fibrosis (CF) due to nonspecific early symptoms.
  • Advocacy for newborn screening to facilitate early intervention.
  • Implementation of a nationwide CF newborn screening program in Switzerland since January 2011.

Purpose:

  • To reduce diagnostic delays for cystic fibrosis.
  • To enable timely preventive care for respiratory and nutritional complications.
  • To align with international consensus and established screening practices.

Summary:

  • The Swiss Nationwide Cystic Fibrosis Newborn Screening Program utilizes a two-step approach.
  • The screening process involves an immunoreactive trypsinogen assay.
  • DNA mutation analysis is performed on dried blood samples (Guthrie cards) collected on day 4.

Impact:

  • Potential for earlier detection and management of CF in newborns.
  • Facilitation of early respiratory and nutritional support.
  • Contribution to improved long-term health outcomes for individuals with CF.

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...